The basis for single-fraction stereotactic radiosurgery (SRS) is largely historical in nature and rooted in conventional thinking. This is derived from the original use of SRS in the treatment of arteriovenous malformations (AVMs), where the benefit of single-fraction high-dose radiation is clearly optimal in terms of addressing AVM obliteration kinetics. However, tumor cell kinetics are not the same as AVM obliteration kinetics and therefore may not be optimally addressed by single-fraction SRS. In addition, fractionated (F) SRS, as compared to single-fraction SRS, should allow for sparing of normal tissue damage. The relatively noninvasive nature of SRS allows for the potential of exploiting the use of FSRS and also allows for consideration of delivering FSRS in a split-course fashion.
Introduction
Developed in 1951, stereotactic radiosurgery (SRS) is a noninvasive surgical approach that has been utilized to treat a wide variety of benign neurological disease and has only in the last decade developed an increasing role in the management of malignant brain tumors (1) (2) (3) . Malignant neoplasms of the central nervous system account for approximately 2-5% of human cancers. One half to 60% of these are gliomas, the majority of which are astrocytomas (4, 5) . The principal pattern of failure for astrocytomas is local. Reasons for local failures can be attributed to surgical factors (suboptimal debulking), radiation factors (inadequate dose and/or geographical miss) or the natural history of the neoplasm. Historical methods for improving the likelihood of local tumor control have been minimally effective. Surgery has been limited by the lack of obvious anatomic distinction between tumor and adjacent normal brain tissue, as well as by a significant risk of permanent neurologic damage associated with more aggressive attempts at surgical resection. Conventional external beam radiation therapy (CEBRT) is limited by the significant risks of normal brain injury associated with high doses required to obtain local tumor control (6). The use of stereotactic brachytherapy in combination with CEBRT, has been associated with improvements in local disease control and survival among appropriately selected patients with high-grade gliomas (7) (8) (9) (10) (11) . Brachytherapy allows much greater escalation of the radiation dose within a well defined volume than is achievable with CEBRT. However, even in patients with well defined tumors, the potential risks associated with brachytherapy implantation in patients with coexisting medical illnesses, or for tumors located in relatively inaccessible parts of the brain, or in close vicinity to critical neurologic structures, may be unacceptable. SRS, utilizing a single large dose of irradiation as a well collimated beam to a small treatment volume, has increased in popularity. SRS allows for the delivery of a high dose of radiation to a tumor volume with rapid fall off of the dose, similar to that obtained with brachytherapy. Unlike brachytherapy, the procedure is non-invasive and is much more feasible due to fewer anatomic constraints of tumor location. Initially such treatments were primarily used for the management of arteriovenous malformations (AVM) (12, 13) . Most experiences with SRS in the management of patients with unfavorable gliomas has thus far involved the use of single large dose fractions (i.e., as used for AVM) given in combination with a course of . Given the improvements in both local control and survival seen with the use of stereotactic brachytherapy, in the order of 50-60 Gy over 5-6 days given in combination with CEBRT, it is unlikely that singledose (10-20 Gy) SRS in combination with CEBRT will offer equal improvements, as the total biological tumor dose is less. In addition, the use of single large fractions may be a radiobiologic disadvantage in these malignant tumors due to the presence of hypoxic and noncycling tumor cells (20) . The use of FSRS and CEBRT in combination should theoretically be complimentary and lead to improved results in the treatment of patients with primary gliomas. It is with this perspective results from our recently reported phase I study are included in this review (21). This perspective will also review the complementary role of whole brain radiation therapy (WBRT) to that of SRS in the management of brain metastases. Brain metastases affect up to 25% of all cancer patients (22, 23) . Conventional treatment of both single and multiple brain metastases includes WBRT. Even when conventional CT or MRI shows no residual tumor after surgical excision or no additional tumor(s) beyond that treated by SRS, WBRT is usually administered in conjunction with these procedures. The use of WBRT is based on the rationale that additional small or microscopic metastases not detected by standard CT or MRI will, if left untreated, eventually cause associated neurologic morbidity and mortality. The addition of WBRT may also decrease the local recurrence rate of metastases treated with surgical excision or SRS (24, 25, 26) . Given its relatively noninvasive nature and ability to be performed as an outpatient procedure, SRS has had an increasing role in the primary management of patients with brain metastases. This, along with the relatively poorly understood but potential risk of neurcognitive sequelae in long terms survivors of patients with brain metastases receiving treatment with WBRT (27,28) has lead to increasingly reported experiences withholding WBRT as part of primary therapy for brain metastases. While none of the analysis from these experiences have shown an overall significant survival difference comparing SRS alone to that of SRS given in conjunction with WBRT (24, [29] [30] [31] ; none of these experiences have analyzed the risk of symptomatic brain tumor recurrence (BTR) and neurologic deficit following use of SRS alone in the treatment of patients with newly diagnosed brain metastases. Our clinical experience evaluating the risk of symptomatic BTR and neurologic deficit in patients treated with SRS alone as initial management for newly diagnosed brain metastases are reviewed along with its implications reinforcing the potential complimentary role of WBRT to that of SRS (32).
Emerging Role of FSRS in the Management of Primary Brain Tumors

University of Kentucky Experience
In 1995 the University of Kentucky activated a phase I study of combined FSRS and CEBRT in the treatment of unfavorable intracranial tumors (21). Eligibility criteria for study enrollment included: (a) histologic confirmation of malignant or unfavorable low grade glioma (b) postoperative or postbiopsy residual tumor of < 30cc (approximately 4 cm in greatest diameter). The treatment schema is shown in Table I treatment volume correlating with the incidence of brain necrosis (i.e., larger volumes tolerate less dose [33]) patients were stratified into 3 groups according to the postoperative/biopsy residual tumor volume (TV). Group A: TV < 5cc; Group B: 5cc < TV < 15cc; and Group C: 15cc < TV < 30cc.
Group A: 14 Gy given in 2 equal fractions, on alternate days, pre-and post CEBRT. Group B: 14 Gy given in 2 equal fractions, on alternate days, pre-CEBRT and 7 Gy in one fraction post-CEBRT. Group C: A single fraction of 7 Gy given preand post-CEBRT. CEBRT began between 1 and 2 weeks following pre-CEBRT FSRS. A minimum of 3 patients with at least 3 months follow-up from completion of treatments were evaluated for toxicity for each fractionation scheme within each patient group. Unacceptable toxicity was defined as acute CNS toxicity which was either irreversible Radiation Therapy Oncology Group (RTOG) grade 3 or any grade > 4 in severity (34). Dose escalation was to involve the addition of single fractions of 7 Gy given on alternate days, either pre/post-CEBRT, to the initially evaluated fractionation scheme within each treatment group to a maximum of 21 Gy given in 3 equal fractions on alternate days, pre-and post-CEBRT. MRI response was determined and defined as that previously reported in the literature with a partial response being > 50% reduction in tumor size measured at the largest cross-sectional diameter times the largest perpendicular diameter (35). A minor response was defined as a > 20% reduction in the multiple of the cross-sectional diameters.
Fourteen patients, 31-77 years (median 57 years), were entered on study. Eight patients had malignant gliomas (6, glioblastoma multiforme [GBM]; 2, anaplastic astrocytoma); 5 had 'unfavorable' low-grade gliomas and 1 patient had recurrent glioma (gemistocytic astrocytoma). Post biopsy/operative residual TV ranged from 2.1-27.2cc (median = 7.4cc) with 3 patients in group A, 6 patients in group B and 5 in group C. All patients were able to complete CEBRT without interruption or experiencing disease progression. Eleven patients (79%) have had partial (N=2) or minor (N=9) MRI response which range from 21%-50% (median = 28%). Six of 9 patients with malignant/recurrent glioma had partial or minor response ranging from 22%-50% (median = 28%). Four of 5 patients with 'unfavorable' low-grade glioma had partial or minor response ranging from 21% -50% (median = 27%). Unacceptable toxicity has been limited to patients in group B (grade 4, N=2/6) and C (grade 4, N=2/5). Three patients experienced unacceptable toxicity and had reoperation. A fourth patient, in group B, experienced an increased neurolgic deficit (grade 4) characterized by seizures and associated hemiparesis with imaging showing decreased tumor size. Current follow-up ranges from 9 -79 months (median = 15 months) with survival curves shown in Figure 1 .
While our preliminary findings and the phase I nature of our study cannot yet adequately address the success of our approach and/or design in supporting the discussed rationale, we can at this point conclude the following: (a) the ability of these patients with unfavorable gliomas to complete CEBRT without experiencing treatment interruptions or disease progression, as well as imaging response findings, is extremely encouraging, and (b) combined FSRS and CEBRT as evaluated thus far in this study is associated with excessive toxicity in patients with Group B/C lesions because of their larger size. Evaluation of this novel treatment strategy with dose modification in patients with group B/C lesions is ongoing.
Considerations and Future Directions of FSRS
The basis for single-fraction SRS is largely historical in nature and rooted in conventional thinking. This is derived from the original use of SRS in the treatment of AVMs, where the benefit of single-fraction high-dose radiation is clearly optimal in terms of addressing AVM obliteration kinetics (36, 37) . However, tumor cell kinetics are not the same as AVM obliteration kinetics and therefore may not be optimally addressed by single-fraction SRS. In addition, FSRS, as compared to single-fraction SRS, should allow for sparing of normal tissue damage.
While some published retrospective experiences have suggested a survival benefit with use of single-fraction SRS (15, 19, 38) , others have shown no obvious survival advantage (16-18). While this may be in part due to patient selection, it may be related to the less than optimal radiobiologic nature of single-fraction boost therapy. This is particularly so for malignant gliomas, known to have cells in an accelerated growth phase at diagnosis and/or during CEBRT. This leads up to 21-33% of these patients being unable to complete a course of CEBRT due to disease progression (14, 39) . In addition, the tumor hypoxia associated with these neoplasms and their potential to undergo accelerated tumor repopulation during the latter phase of CEBRT, as seen in head and neck tumors (40, 41) , is also likely to further minimize any impact of single-fraction boost therapy. The relatively noninvasive nature of SRS allows for the potential of exploiting the use of FSRS and also allows for consideration of delivering FSRS in a split-course fashion, as performed in our study. This provides an additional advantage over what can normally be achieved by use of stereotactic brachytherapy, in that stereotactic brachytherapy is likely to be performed only once in the course of a patient's primary treatment. This feasibility, along with the previous discussion, serves as the rationale of our study design combining FSRS boost in a split-course fashion pre-and post-CEBRT. This strategy exploits tumor and/or normal tissue cell kinetics, inclusive of attempting to counteract the initial accelerated tumor growth phase pre-CEBRT, thereby decreasing the rate of clinical tumor progression during CEBRT. This split-course design should also help to counteract the effect of accelerated tumor repopulation post-CEBRT.
The limitation in a potential survival benefit being associated with use of single-fraction SRS will be addressed by RTOG study 93-05, a recently closed 200 patient trial that randomized GBM patients to CEBRT plus BCNU with or without single-fraction SRS. Regardless of the results of this RTOG study there will clearly be room for improvement. Hence, a national phase II trial (RTOG 00-23) has been recently activated evaluating use of combined CEBRT and FSRS in patients with newly diagnosed GBM.
The Complimentary Role of WBRT in the Management of Brain Metastases
Local tumor control with SRS -impact of WBRT Table II summarizes the local tumor control of brain metastases treated with SRS with or without the addition of WBRT. In a multi-institutional retrospective review of SRS in the treatment of single brain metastases reported by Flickinger et al, SRS combined with planned WBRT was associated with improved local control as compared to use of SRS without planned WBRT (24). This finding was most dramatic among the 71 patients treated for newly diagnosed brain metastases; with those receiving planned WBRT having a one-year local tumor control rate of 82% as compared to 47% for those treated with SRS alone (P = 0.008). Pirzkall et al. (29) reviewed 236 patients with 1-3 brain metastases and no previous WBRT. The combination of SRS and planned WBRT resulted in an increased local tumor control rate as compared to SRS without planned WBRT, although only as a trend in the overall series. Actuarial local control rates for patients who received SRS with planned WBRT were 92% and 86% at 1 and 2 years after treatment, respectively, compared with 89% and 72% for patients treated with SRS without planned WBRT (P = 0.13).
Another recent retrospective review of patients with newly diagnosed brain metastases by Chidel et al. (31) compared 57 patients treated with combined SRS and planned WBRT to 78 patients managed initially by SRS without planned WBRT. Local tumor control at 2 years was 80% in patients treated with SRS and planned WBRT as compared to 52% for patients receiving SRS without planned WBRT (P = 0.034).
The most significant factor in our series (26) on multivariate analysis found to influence local tumor control with 20 Gy SRS for two hundred and thirty-four < 2 cm brain metastases was the addition of planned WBRT. Patients receiving planned WBRT had an overall tumor control rate of 98% as compared to 81% for those not receiving planned WBRT with 20 Gy of SRS (P=0.002, Figure 2 ). 
Use of SRS alone -implications for adjunctive WBRT
We recently reported on 36 consecutive patients with newly diagnosed brain metastases treated at the University of Kentucky with SRS alone (i.e., no WBRT as part of initial brain metastases management) (32). All patients had previously untreated brain metastases with no prior history of craniotomy and/or WBRT. WBRT was not given as part of initial brain metastases management due to patient and/or physician preference. Patients were followed with neurologic examinations by neurosurgeons or neurologists and high-resolution MRI imaging every 2 to 5 months (median = 3 months). Development of a neurologic deficit was defined by a change in neurologic status including, but not limited to, objective decrease in strength, degradation in ambulatory function, alteration in mental status, development of aphasias, or changes in vision or sensation. The primary end points of this analysis was the risk, and associated morbidity, of BTR. To better describe and quantify the morbidity associated with BTR, BTR was scored as either being asymptomatic or symptomatic. In addition, the progression and/or development of a new neurologic deficit in associa-tion with a BTR was scored and used to define neurologic deficit-progression free-survival.
Seventeen patients (47%) experienced BTR at 1 to 12 months (median = 4) following SRS. On multivariate analysis, the only factor found to be predictive of BTR was disease status at diagnosis. Eight of 10 (80%) patients with disease limited to the brain only experienced BTR as compared to 9 of 26 (35%) patients with brain plus other sites of disease (p = 0.03). The actuarial risk of BTR with time is shown in Figure 3 . BTR was symptomatic in 12 (71%) of the 17 patients and was associated with a neurologic deficit in 10 (59%). The actuarial neurologic deficit-progressionfree survival is shown in Figure 4 .
In 1998, Patchell et al. (25) reported the results of phase III trial evaluating the role of post-operative WBRT in the treatment of patients with single brain metastases. While this series is somewhat limited in comparison to previously discussed series of SRS given the use of surgery, it provides a useful critique within a randomized setting as to the efficacy of WBRT in eliminating undetected micrometastases elsewhere in the brain and as to the relative effectiveness of WBRT when used as salvage therapy rather than as part of primary management. Overall the BTR rate was less frequent in the WBRT group as compared to the observation group (18% vs 70%; p < 0.001). This benefit was seen at both the original site of metastases and distant sites within the brain. Patients in the WBRT group were also less likely to die of neurologic causes than patients in the observation group (14% vs 44%; p = 0.003). In addition, these benefits were not seen in the 32 patients (70%) within the observation group who experienced BTR. This is despite the majority of these patients having access to SRS and 29 (91%) being able to undergo attempted salvage brain therapy (42).
A number of recent studies have shown that a treatment strategy limited to the site of brain metastases only (i.e., Surgery or SRS) is associated with an increased risk of BTR both at the site of initial brain metastases as well as elsewhere in the brain. (24, 25, (29) (30) (31) . As shown these studies, particularly those evaluating use of SRS, are limited by the lack of information on neurologic outcome and quality of life particularly impacted by the associated increased risk of BTR in patients treated with SRS alone. The lack of information with regards to neurologic outcome is inclusive of the potential decrement in neurocognition which may be associated with the increased risk of BTR. In a secondary analysis of RTOG study 91-04, a randomized phase III study of accelerated hyperfractionation (AH) versus standard accelerated fractionation (AF) in over 300 patients with unresected brain metastases, BTR was associated with a detrimental effect on neurocognitive function. Use of AH as compared to AF-WBRT was unassociated with a significant difference in 
Stereotactic Radiosurgery 47
Figure 3: Actuarial brain tumor recurrence curve for patients (N=36) with newly diagnosed brain metastases treated with SRS alone.
Figure 4:
Actuarial neurologic deficit progression-free survival curve for patients (N=36) with newly diagnosed brain metastases treated with SRS alone. neurocognitive function as measured by the Mini-Mental Status Exam (MMSE) in this patient population with unresectable brain metastases and limited survival. However, control of brain metastases was the only factor found to have a significant impact on MMSE. It was only among patients with "uncontrolled" brain metastases that a significant drop in MMSE score was seen. At 3 months the average change in MMSE score was a drop of 0.5 for those whose brain metastases were radiologically controlled as compared to a drop of 6.3 for those with uncontrolled brain metastases (p=0.02) (43).
In patients with newly diagnosed brain metastasis selectively treated with SRS, the addition of WBRT should be considered as the mainstay of treatment, particularly for those patients in whom the potential for prolonged survival can predicted. In the meantime, prospective trials are needed to evaluate the use of primary SRS alone vs combined SRS and WBRT evaluating patients through salvage therapy while collecting data on BTR rates, neurologic deficit-progression-free survival, neurocognitive function, and quality of life.
Conclusions
SRS is a fledgling therapeutic cancer technology, the optimal use of which remains to be seen. Further exploitation of tumor cell kinetics by use of fractionated SRS is currently under investigation, particular in patients with primary brain tumors. Optimal integration of SRS with selective use of WBRT in patients with brain metastases continues to be explored
